J&J Extends Delay In Returning Some OTCs To Market
This article was originally published in The Tan Sheet
Executive Summary
CFO Caruso says operating under a consent decree with “a third party in the manufacturing facilities with us” makes it “very difficult for us to predict exactly when products will return.” Some products will not return to stores until 2013, significantly later than the original goal to relaunch all recalled liquid OTCs before 2012.
You may also be interested in...
J&J CEO Choice Likely Will Not Raise Consumer Business Profile
Alex Gorsky will replace William Weldon as Johnson & Johnson CEO in April. Like his predecessor, who has led during a time of extensive OTC recalls, Gorsky’s experience with J&J comprises management of Rx pharmaceutical and medical device businesses, with no consumer background.
McNeil Recalls Liquid Infants’ Tylenol With Dosing Device Problem
McNeil Consumer Healthcare recalls an Infants’ Tylenol product that returned to market in November, after receiving consumer complaints about a problem with the SimpleMeasure dosing device system. The recall marks a misstep in the J&J subsidiary’s comeback from OTC quality control issues.
J&J’s Caruso Pitches OTC Comeback To Analysts
Johnson & Johnson will not “shortchange” its commitment to returning its recalled consumer brands to the marketplace, Chief Financial Officer Dominic Caruso says.